Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 7/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620541 | 0.83 | KCNH2 (0.45) | KCNA3CKS1BSKP1SKP2ATM | |
| SCHEMBL622206 | 0.82 | PIK3CA (0.45) | KCNA3CKS1BSKP1SKP2ATM | |
| SCHEMBL15661283 | 0.80 | LTA4H (0.45) | DRD2HTR7ADRA1AADRA1BDRD3 | |
| SCHEMBL620506 | 0.80 | KCNA3 (0.46) | KCNA3CKS1BSKP1SKP2ADRA1A | |
| SCHEMBL621906 | 0.78 | KCNA3 (0.44) | KCNA3CKS1BSKP1SKP2DRD2 | |
| SCHEMBL14610728 | 0.74 | KCNH2 (0.66) | KCNA3 | |
| SCHEMBL31623742 | 0.74 | KCNH2 (0.66) | KCNA3 | |
| SCHEMBL17861339 | 0.73 | CKS1B (0.50) | CKS1BSKP1SKP2PARP1 | |
| SCHEMBL10313860 | 0.73 | KCNH2 (0.51) | KCNA3CKS1BSKP1SKP2ATM | |
| SCHEMBL8302728 | 0.72 | TSHR (0.48) | KCNA3DRD2HTR7HTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basiliea Pharmaceutica AG | 2015-03-19 | — | — | US | disclosed |
| US-8927542-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2014-08-07 | — | — | US | disclosed |
| US-8716280-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
| EP-2389376-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010084152-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | KCNA3 546/4885CKS1B 1787/4885SKP1 4380/4885 |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | KCNA3 643/4885CKS1B 699/4885SKP1 4119/4885 |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | KCNA3 643/4885CKS1B 699/4885SKP1 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.